Related Blog Posts from the Wikinvest Wire

Generic drug companies are standing on the cusp of a once-in-a-lifetime opportunity. In the next five years, a total of $290 billion in prescription drug sales are expected to lose patent protection, making brand-name pharmaceutical companies vulnerable to generic competition. The effect this so-called "patent cliff" will have on the generics space cannot be overstated. Take cholesterol [...]

On Monday, Pfizer Inc. (NYSE:PFE) announced plans to purchase an attention-deficit/hyperactivity (ADHD) disorder drug developer, NextWave Pharmaceuticals. The deal could carry a $700 million value. During the second quarter, Pfizer paid $20 million for an option payment of the company, to open up a merger agreement. Upon the deal's close, the company will pay $255 million, [...]

Pfizer Inc. (PFE) recently announced European Commission approval of its renal cell cancer drug, Inlyta (axitinib). Inlyta gained approval from the EC for use in treatment-failed patients (prior treatment with Sutent (sunitinib or a cytokine) with advanced renal cell carcinoma (RCC). Approval was largely expected as, earlier this year, the Committee for Human Medicinal Products (CHMP) [...]

The US Food and Drug Administration (FDA) recently extended its review period for Pfizer’s (PFE) rheumatoid arthritis (RA) candidate, tofacitinib. The FDA will deliver a decision regarding the approvability of tofacitinib by November 21, 2012. Pfizer is looking to get tofacitinib approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis. The [...]

Pfizer, Inc. (PFE) recently announced disappointing late-stage results on intravenous (IV) bapineuzumab. Bapineuzumab is being developed under Pfizer and Johnson & Johnson’s (JNJ) Janssen Alzheimer Immunotherapy R&D LLC's Alzheimer’s Immunotherapy Program (AIP). Pfizer and Janssen AI are partners in AIP and Elan Corporation (ELN) has a 49.9% interest in Janssen AI following its September 2009 [...]

Pharmaceutical major Pfizer Inc. (NYSE:PFE) has been reported to have agreed to pay $60 million to the federal government, in settlement of alleged charges that its employees were involved in the bribery of overseas officials and prescribing doctors in Europe and in Asia, in order to generate business. Pfizer Inc. (NYSE:PFE) had been charged under the Foreign Corrupt [...]

Pfizer Inc. (NYSE:PFE), the largest US drug manufacturer by revenues, easily beat Wall Street expectations in its quarterly earnings report for the period of Apr-June 2012.  The one time earnings per share (excluding special items), was 62 cents per share which compared favorably with the EPS of 59 cents in the corresponding quarter of 2011. The street expected 54 [...]

In yesterdays blog post I mentioned Pfizer's (PFE) travails of the last few years and thought that a reader at Seeking Alpha would make a comment about being happy that their stocks stayed down.

Many remain concerned about the global economy and the developing situation in Europe, and this has had a negative impact on Pfizer (PFE) stock, along with many others. Recent news for the company has been mostly positive, but some negative news will likely cancel out the effects of these stories. Based on recent news, I [...]

Pfizer Inc. (NYSE:PFE) has moved one step closer to approval of a drug that will improve options in the treatment of Rheumatoid Arthritis. An advisory panel specializing in arthritis medication voted 8-2 in favor of the drug stating that it's benefits outweighed its potential risks. The support of the committee brings the company one step [...]

By Morgan Smith Pfizer (PFE) released first quarter 2012 results on May 1, coming in slightly above analyst expectations despite decreased revenues. Analysts expected adjusted earnings of $0.56 per share and Pfizer reported adjusted earnings at $0.58 per share on reported revenues of $1.5 billion. Just a week prior, competitor Merck (MRK) posted similar earnings per [...]

About three months ago, I wrote a Money and Markets column that said I was going to start helping my dad generate more income from his dividend stocks by writing covered call options [...]

by Larry Gellar On an otherwise dreary day for the markets, Pfizer (PFE) announced Monday that Nestle (NSRGY.PK) will buy the company's highly coveted infant-nutrition business. Once the downward momentum from negative news in Europe subsides, I highly recommend investors take a look at Pfizer's stock. This was a crucial step in Pfizer's plan to focus [...]

Nestl'e SA, the world's largest food maker, has agreed to acquire Pfizer Inc.'s (NYSE: PFE) baby food business for a hefty $11.9 billion. Nestl'e outbid potential rivals like Danone SA and Mead Johnson Nutrition Co. (NYSE: MJN). Chris Hogg, a spokesperson for Switzerland-based Nestle, said the company will be funded entirely through debt, "namely through internal cash resources and through the bond markets." In a statement, Nestle CEO Paul Bulcke said, "Pfizer Nutrition is...

Pfizer (NYSE:PFE)’s heart pill Inspra has gained a new license in the UK.

Pfizer (NYSE:PFE) and Biocon have announced the conclusion of their commercialization agreement.

Courtesy of ZeroHedge. View original post here.Submitted by testosteronepit.Wolf Richter   www.testosteronepit.com Economic, regulatory, and entitlement reforms are tough. While they’re supposed to open opportunities, put budgets on sounder footing, or make the economy more competitive, they invariably cut into the flesh of some groups, who then react with demonstrations and strikes to draw attention to [...]

Pfizer (NYSE:PFE) and leading veterinary medical schools have collaborated for advanced veterinary medical education in China.

David Einhorn has made an impressive name for himself with his Greenlight Capital Re, Ltd. (NASDAQ:GLRE) and his recent lucrative, although brief career with Lehman Brothers. What begin with a meager $900 K, Greenlight Capital Re, Ltd. (NASDAQ:GLRE) has developed into one of the highest price to earning ratio investment firms in the industry. What is [...]

Pfizer (NYSE:PFE) has expanded its three-year research agreement with the California Institute for Quantitative Biosciences.Pfizer Expands Research AgreementThe drug maker giant Pfizer (NYSE:PFE) has reached an agreement to renew a three-year agreement with California Institute for Quantitative Biosciences (QB3) to collaborate on research projects at the University of California with the potential to transform world-class [...]

Pfizer (NYSE:PFE) has become an official partner of the First World Congress on Healthy Ageing.Pfizer becomes Healthy Ageing PartnerAs a part of the move to reaffirm the company’s commitment to promote healthy and active ageing at all stages of life, the US based drug maker giant Pfizer (NYSE:PFE) has agreed to become an official partner [...]

By Morgan Smith The pharmaceutical industry is like a bad episode of Desperate Housewives - long-term commitments are broken, homes are divided, new alliances are formed, and changing bedfellows is par for the course. Only, in this case, the culprit isn't the dredges of suburbia, but rather an evolution of sorts. Pharmaceutical companies are constantly developing new [...]

It was revealed on Friday that Nestle will do battle with a team made up of Danone and Mead Johnson (NYSE: MJN) for Pfizer's (NYSE: PFE) infant nutrition business. According to the Chicago Tribune, the PFE unit being sold is a high-growth $2.1 billion turnover business with over 70% of sales in emerging markets and a key position in China. It has now attracted the attention of the companies widely considered the three largest players in infant milk formula. Most analysts and bankers are...

Financial Analysis: Pfizer Inc (NYSE:PFE) reported its total revenue to $16.74 billion for the period ending December 31st, 2011 as compared to revenue of $17.35 billion for the same period last year. However despite decrease in sales the company’s profits surged. The net income soared to $1.43 billion or earnings of $0.34 per share for the [...]

Pfizer (NYSE:PFE) has decided to raise $3 billion through a part-flotation of its animal health division.Pfizer Plans $3bn FloatationAccording to a Financial Times report, the US based drug maker giant Pfizer (NYSE:PFE) is weighing plans to raise about $3 billion this year through a part-flotation of its animal health division.The company is in discussions with [...]

Pfizer (NYSE:PFE) has appointed a new head to lead its Veterinary Business Solutions.Pfizer Makes Vet Business ChangeAccording to an announcement made by the company, the Animal Health unit of Pfizer (NYSE:PFE) has appointed Steve Sornsen as the new senior director for its Veterinary Business Solutions unit.In his new role, he will be responsible for leading [...]

A key challenge in the pharmaceutical industry these days is the staggering amount of drugs losing their patent protection. Back in November 2011, Pfizer's (NYSE: PFE) Lipitor -- the company's all-time best-selling drug, which reported annual sales in excess of $10 billion at its peak -- lost its patent protection. In 2012, least branded drugs [...]

Pfizer (NYSE:PFE) has awarded a donation for Windsor Regional Hospital in Canada.Pfizer (NYSE:PFE) Donating To Canada HospitalThe US based drug maker giant Pfizer (NYSE:PFE) has provided a $30,000 donation for Windsor Regional Hospital in Canada that will help establish a clinic to house the Wellness Program for Extended Psychosis.Sarah Mitton, Pfizer (NYSE:PFE) brand manager said, [...]

Those of you who remember the introduction of the drug Viagra to the in 1998 will agree it was a game-changer for the pharmaceutical markets. The same thing is happening in the American oil and gas shale boom.

By Kathleen Martin Pfizer Inc. (PFE) is a research-based, global biopharmaceutical company. The stock trades around $21.80. The year high was $21.83 and the low was $16.63. The enterprise value is $179.96 billion, the market cap is $167.81 billion and revenue is $68.78 billion. Fully-diluted earnings per share are 1.44. The company has total cash [...]

Pfizer (NYSE:PFE) has commissioned an e-pharmacy project at the Lagos University in Nigeria.Pfizer (NYSE:PFE) To Begin Nigeria ProjectThe US Based pharmaceutical giant Pfizer (NYSE:PFE) has commissioned an e-pharmacy pilot project at the Lagos University Teaching Hospital(LUTH), Idi-Araba, aimed at creating a pool of credible and realizable data that can be used in a globally accepted [...]

Peregrine Pharmaceuticals (NASDAQ: PPHM) has traditionally been an unknown biopharma player. Until now, that is. Peregrine may have uncovered a compound that has extremely high efficacy for lung cancer tumors. If this news ends up being statistically significant, Peregrine could be sitting on a blockbuster drug. Peregrine Pharmaceutical currently has a drug, called Bavituximab, that is currently undergoing Phase II FDA trials. As of now, it has been able to show a 50% improvement in tumor...

November 30, 2011 was a big day for Pfizer, Inc. (PFE) with its blockbuster cholesterol drug, Lipitor, losing exclusivity in the US. With so many drugs losing exclusivity, why is the loss of exclusivity of Lipitor such a major event? Well, Lipitor has been a huge revenue generator and its loss of exclusivity could very [...]

Teva Pharmaceuticals (NASDAQ: TEVA) is one of the few pharmaceuticals that struck when the time was right when Lipitor expired. Pfizer's (NYSE: PFE) drug brought in approximately $7.8 billion, and revenues are almost guaranteed to decline significantly as a result of patent protection. Teva Pharmaceuticals is poised to profit handsomely from Lipitor simply because of its plans with the drug. It will be targeting markets in the US, Europe, and Asia. This gives it significant revenue streams...

Pfizer this morning announced a buyout of privately-held Excalliard. Excalliard is developing EXC001, an antisense drug against CTGF for scarring (their trials to date have been in abdominal and breast revision surgery). You can get more info on the drug, clinical trials, and some photos of results on my ISIS research page. This is a surprise [...]

Pfizer (NYSE:PFE) has partnered with MIT to open a new research centre in Massachusetts.Pfizer (NYSE:PFE) To Open MIT Research CentreThe drug maker giant Pfizer (NYSE:PFE) and the Massachusetts Institute of Technology (MIT) have announced the official groundbreaking on their new location of Pfizer (NYSE:PFE)'s Cardiovascular, Metabolic and Endocrine Diseases (CVMED) and Neuroscience research units.Mikael Dolsten, [...]

Pfizer (NYSE:PFE) has decided to pay about $60 million to settle bribery probe.Pfizer (NYSE:PFE) To Settle Bribery Probe With $60mReports say that the drug maker giant Pfizer (NYSE:PFE) has agreed to pay more than $60 million to settle an investigation by U.S. regulators into whether the drugmaker paid bribes to win business abroad.People familiar with [...]

Pfizer (NYSE:PFE)’s Vyndaqel drug has been approved by European Commission for symptomatic polyneuropathy treatment.Pfizer (NYSE:PFE) Wins Euro Drug ApprovalAccording to an announcement made by Pfizer (NYSE:PFE), the European Commission has approved its Vyndaqel(R) (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy.Yvonne Greenstreet, senior vice president [...]

Pfizer (NYSE:PFE) has launched the Robitussin flu tracker application.Pfizer (NYSE:PFE) Helps You Find (And Avoid) Flu On iPhoneThe new Robitussin Relief Finder 2.0, a free iOS app that allows users to track flu activity nationwide, has been launched by the drug maker giant Pfizer (NYSE:PFE).This application can also be used to find nearby stores that [...]

Pfizer $PFE held a webcast related to Rheumatoid Arthritis around the American College of Rheumatology meeting last week. Click here to download the slides deck (PDF). See below for a few helpful notes and figures related to the RA market Related: CLICK HERE FOR FREE GOOGLE EMAIL ALERTS WHEN WE POST A NEW ARTICLE Market size was $12.7b in 2010, projected [...]

Pfizer (NYSE:PFE) has decided to extend its Prevenar vaccine to rural China.Pfizer (NYSE:PFE) Plans China ExpansionThe world's largest drug maker Pfizer (NYSE:PFE) is planning to push sales of its Prevenar vaccine across China in collaboration with partner Shanghai Pharmaceutical and possibly other new partners.Mark Swindell, Pfizer (NYSE:PFE)'s global president for vaccines said, “The way to [...]

Pfizer (NYSE:PFE) has partnered with Children's Hospital in Boston on its Duchenne muscular dystrophy program.Pfizer (NYSE:PFE) Makes Boston DealUnder this new collaboration, the drug maker giant Pfizer (NYSE:PFE) and Children's Hospital Boston will work together on a drug discovery program focused on Duchenne muscular dystrophy (DMD).Ed Mascioli, M.D., Vice President and Chief Scientific Officer of [...]

Pfizer (NYSE:PFE) has opened a new animal health equine research centre in Michigan.Pfizer (NYSE:PFE) Opens Animal CenterThe animal health unit of the US based drug maker giant Pfizer (NYSE:PFE) has opened a new Equine Research Center in Richland, Michigan.Dr. Cathy Knupp, vice president of Veterinary Medicine Research and Development for Pfizer (NYSE:PFE) Animal Health said, [...]

Pfizer (NYSE:PFE) has decided to present clinical data from its hematology portfolio at the Annual Meeting of the American Society of Hematology.Pfizer (NYSE:PFE) To Present On HematologyThe pharmaceutical giant Pfizer (NYSE:PFE) will present data on a number of investigational compounds from its hematology portfolio at the upcoming 53rd Annual Meeting of the American Society of [...]

ABOUT Pfizer Inc. (NYSE:PFE): Pfizer was incorporated in 1849 and situated in New York, New York. PFE is a research based global biopharmaceutical company which operated its business into two segments: 1 Biopharmaceutical 2 Diversified Biopharmaceutical provides the primary care, specialty care; established products, emerging markets and oncology customers focused units. The company focuses on the treatment of cardiovascular [...]

"One pill makes you stronger, and the other makes you small." -"White Knight", Jefferson Airplane With Pfizer's earnings, you are looking for the pills to make you significantly stronger, with shares are up around 2% amidst a broadly weaker market today. Pfizer (NYSE: PFE), the New York-based pharmaceutical company reported third quarter earnings this morning that handily beat Wall Street analysts. The company reported third quarter earnings of 62 cents per share on $17.2 billion in...

Pfizer (NYSE:PFE) has entered into a research collaboration with Medco Health Solutions.Pfizer (NYSE:PFE) Enters Medco DealThe world’s largest drugmaker company Pfizer (NYSE:PFE) has reached a research collaboration with Medco Health Solutions and its subsidiary United BioSource Corporation aimed at better identifying the patients most likely to be helped by a new medicine.Freda Lewis-Hall, M.D., Pfizer [...]

Pfizer (NYSE:PFE) has organized free eye screening services in Nigeria.Pfizer (NYSE:PFE) To Offer Free Eye-ScreeningAs a part of its corporate social responsibility and efforts to forestall the onset of preventable eye disorders such glaucoma and trachoma, Pfizer (NYSE:PFE) recently held a free eye screening services in Abuja, Ilorin, Kano and Osun states in the country.Enrico [...]

Pfizer (NYSE:PFE) has agreed to pay $14.5 million to settle marketing charges.Pfizer (NYSE:PFE) To Pay $14.5m SettlementThe US based drug maker giant Pfizer (NYSE:PFE) will pay the government about $14.5 million to settle charges it illegally marketed its drug for a condition called overactive bladder.The settlement disclosed Friday resolves the last of 10 whistleblower lawsuits, [...]

Pfizer (NYSE:PFE) has agreed to pay $177,000 to the Massachusetts Medicaid program for off-label marketing settlement.Pfizer (NYSE:PFE) To Pay Medicaid SettlementAs part of a nationwide settlement over allegations of illegal off-label marketing, the drug maker giant Pfizer (NYSE:PFE) is paying more than $177,000 to the Massachusetts Medicaid program.This settlement with Pfizer (NYSE:PFE) will resolve allegations [...]